Expression of receptor activator of NF-κB ligand (RANKL) mRNA in human multiple myeloma cells
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
- Charité – Universitätsmedizin Berlin
- University of Göttingen
Abstract
Purpose: Increased bone resorption is a hallmark of multiple myeloma and a result of excessive osteoclast activation. Recently, the receptor activator of NF-κB ligand (RANKL) was found to be the critical factor for osteoclastogenesis. Studies showed that myeloma cells induce RANKL expression in bone marrow stromal cells, but it remained a controversy whether myeloma cells directly express RANKL. Methods: Therefore, we analyzed the expression of RANKL mRNA in freshly isolated CD138 positive plasma cells from patients with multiple myeloma and osteolytic bone lesions, using three different primer pairs against human RANKL. Results: RANKL mRNA could be detected in bone marrow plasma cells from myeloma patients with osteolytic myeloma bone disease. Conclusions: These findings show that myeloma cells directly express RANKL and indicate that specific blockade of RANKL may be an effective treatment for myeloma bone disease.
Details
Original language | English |
---|---|
Pages (from-to) | 469-474 |
Number of pages | 6 |
Journal | Journal of cancer research and clinical oncology |
Volume | 130 |
Issue number | 8 |
Publication status | Published - Aug 2004 |
Peer-reviewed | Yes |
External IDs
PubMed | 15205949 |
---|---|
ORCID | /0000-0002-8691-8423/work/142236153 |
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Multiple myeloma, Myeloma bone disease, Osteoprotegerin, RANK, RANKL